Tamtam Try Tamtam free
Virbac logo

Virbac account plan

Animal health solutions worldwide

At a glance

Virbac is a French animal health company making veterinary medicines, vaccines and petfood, with 2025 revenue of €1,464.7 million.

Virbac is 100% dedicated to animal health and ranks 6th worldwide among veterinary drug manufacturers. It develops, produces and distributes pharmaceuticals, vaccines, nutraceuticals, hygiene products and specialized petfood for companion and farm animals, sold mainly through wholesalers and purchasing groups that supply veterinarians. In 2025 it reported revenue of €1,464.7 million (+7.9% at constant rates and scope), adjusted EBIT of €234.4 million (16.0%) and net profit Group share of €150.9 million. It had 6,442 employees in 37 countries at end-2025, with production sites in 12 countries. The Dick family group holds 50.09% of the capital and 66.21% of voting rights.

Business units

Strategic priorities

Supercharge growth platforms
Under the 'Growing Together' strategy, Virbac focuses on petfood, reproduction, dental, mobility, ear, endocrinology and ruminants; these platforms grew around 12% in H1 2026.
Margin toward around 20%
Virbac committed to move profitability to around 20% and guides an adjusted EBIT margin around 17% for 2026, with revenue growth at the upper end of its 5.5%-7.5% range.
Record R&D
R&D investment was a record €115 million in 2025, 8.7% of revenue, and management plans to increase the share of R&D in revenue.
US scale
The US is described as an absolute priority, and adding scale there is priority #1 for M&A; nearly 80% of US revenue is expected to come from local US production by end-2026.
Omnichannel and direct-to-consumer
Virbac is increasing advertising and promotion as part of the business shifts toward an omnichannel model, partly direct-to-consumer.

Latest results

H1 2026 revenue was €768.0 million, +7.4% at constant exchange rates and +4.0% at actual rates, with growth from volume and mix (about 5.4%) and price (about 2%). Adjusted EBIT rose to €144.2 million, 18.8% of revenue, and net profit Group share to €87.4 million. By region, Europe grew 6.5%, North America 10.1% and International 7.5%. Net debt rose to €195.9 million on seasonal working capital and capex. Virbac now targets the upper end of its 5.5%-7.5% growth guidance, an adjusted EBIT margin around 17% and capex around €125 million.

Investments and deals

Industrial transformation programme
Over €100 million committed to modernize facilities, including a new companion animal vaccine plant in the south of France, a new Suprelorin line, a new petfood plant and a new logistics center; capex around €125 million is guided for 2026.
Thyronorm acquisition
Feline hyperthyroidism treatment acquired in December 2025 from Norbrook, adding about 1 point of 2026 revenue growth; most of Europe comes under direct Virbac management in 2027.
Licensing deals
Porus One and Vetcare licensing deals signed in H1 2026, distributed from 2027 with options for full acquisition.
Quality and digital
€23 million of Quality investments in 2025 and around €25 million of quality upgrades at key sites planned for 2026, alongside record digital and IT investment.

Challenges and risks

Currency headwinds
Currency cut €25 million from H1 2026 revenue, mainly through emerging-market currencies such as the Mexican peso, Brazilian real and Indian rupee.
Supply constraints
France and Belgium were flat in H1 2026 mainly due to supply constraints, and North America faced temporary regulatory hurdles in toll manufacturing and farm animal supply constraints.
Competition and distribution consolidation
Virbac competes with larger players and faces consolidation of distributors and vet clinic networks; Australia saw intense competition in H1 2026.
Hard-to-hire talent
Skills in industry, quality assurance and R&D are hard to hire, notably in France.
Trade and input costs
Active ingredients are sourced from Asia, direct US customs duties are estimated at approximately US $3 million a year, and the Middle East crisis brought oil-driven inflation.

What leadership says

“committed to deliver our 2026 goals while shaping our future through industrial and digital strategic transformation projects and record levels of investments in R&D.”

Paul Martingell, Chief Executive Officer · Opening interview, Annual Report 2025 (April 2026)

“because we believe clearly that in our industry, it's all about innovation”

Paul Martingell, Chief Executive Officer · Animal Health Insider interview, March 14, 2026

“We're not managing a share price.”

Paul Martingell, Chief Executive Officer · Animal Health Insider interview, March 14, 2026

Where a supplier can help

Plant construction and equipment
Tied to the industrial transformation programme: a new vaccine plant, petfood plant and logistics center, with capex expected above €100 million for a few years, open room for engineering, equipment and automation suppliers.
Quality and supply-chain reliability
Tied to the supply constraints challenge and quality investments: offers that improve GMP quality, planning and capacity at constrained sites address issues named in the H1 2026 report.
Omnichannel marketing and DTC
Tied to the omnichannel priority: higher advertising and promotion spend and a partly direct-to-consumer model call for marketing, e-commerce and customer data capabilities.
Recruiting in technical roles
Tied to the hard-to-hire talent challenge in industry, quality assurance and R&D, notably in France.
Digital and IT transformation
Tied to the record digital and IT investment the CEO describes alongside the industrial projects.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Virbac?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Virbac

What does Virbac do?

Virbac develops, produces and distributes veterinary medicines, vaccines, nutraceuticals, hygiene products and specialized petfood for companion and farm animals, sold mainly to veterinarians through wholesalers.

What is Virbac's revenue?

Revenue was €1,464.7 million in 2025, with adjusted EBIT of €234.4 million. H1 2026 revenue was €768.0 million, +7.4% at constant exchange rates.

How many employees does Virbac have?

Virbac had 6,442 employees in 37 countries at end-2025, 25.1% of them in France.

Who leads Virbac?

Paul Martingell has been CEO since September 2025; Habib Ramdani is CFO and deputy CEO, and Marie-Hélène Dick-Madelpuech chairs the board.

What is Virbac's strategy?

Grow above its market through the Supercharge platforms, invest record amounts in R&D and plants, expand through acquisitions with US scale as priority, and lift profitability toward around 20%.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)